

This document is important and requires your immediate attention. If you are in doubt as to how to deal with it you should consult your investment dealer, stockbroker, bank manager, accountant, lawyer or other professional advisor.

No securities regulatory authority in Canada or in the United States has expressed an opinion about, or passed upon the fairness or merits of, the Offer or the adequacy of the information contained in this document and it is an offence to claim otherwise.

This document does not constitute an offer or a solicitation to any person in any jurisdiction in which such offer or solicitation is unlawful. The Offer is not being made or directed to, nor will deposits be accepted from or on behalf of, Shareholders in any jurisdiction in which the making or acceptance of the Offer would not be in compliance with the laws of such jurisdiction. However, the Offeror may, in its sole discretion, take such action as it may deem necessary to extend the Offer to Shareholders in any such jurisdiction.

October 17, 2011



NOTICE OF EXTENSION

1625907 ALBERTA LTD.

A CORPORATION WHOLLY-OWNED BY

VALEANT PHARMACEUTICALS INTERNATIONAL, INC.

OFFER TO PURCHASE FOR CASH

ALL OF THE OUTSTANDING COMMON SHARES
(together with associated rights issued under the Shareholders Rights Plans)

OF

AFEXA LIFE SCIENCES INC.

AT A PRICE OF \$0.85 FOR EACH COMMON SHARE

1625907 Alberta Ltd. (the "**Offeror**"), a wholly-owned subsidiary of Valeant Pharmaceuticals International, Inc. ("**Valeant**"), hereby gives notice that it is extending the period for acceptance of its offer, dated September 6, 2011 (the "**Original Offer**"), as amended by the notice of variation dated October 3, 2011 (the "**Notice of Variation**") to purchase, upon the terms and subject to the conditions of the Offer (as hereinafter defined), all of the issued and outstanding common shares, together with the associated rights (the "**SRP Rights**") issued under the shareholder rights plans described in the Original Offer and Circular (as hereinafter defined) (such common shares together with the SRP Rights, the "**Common Shares**") of Afexa Life Sciences Inc. (the "**Company**" or "**Afexa**"), including Common Shares issued after the date of the Offer but prior to the Expiry Time (as hereinafter defined) upon the conversion, exchange or exercise of any securities of Afexa that are convertible into or exchangeable or exercisable for Common Shares.

THE OFFER HAS BEEN EXTENDED AND IS NOW OPEN FOR ACCEPTANCE UNTIL 5:00 P.M. (EDMONTON TIME) ON OCTOBER 27, 2011 (THE "EXPIRY TIME") UNLESS THE OFFER IS FURTHER EXTENDED OR WITHDRAWN.

ALL OF THE COMMON SHARES DEPOSITED TO THE OFFER AND NOT WITHDRAWN AS OF 5:00 P.M. (EDMONTON TIME) ON OCTOBER 17, 2011, NAMELY, 80,929,921 COMMON SHARES, REPRESENTING APPROXIMATELY 73.8% OF THE OUTSTANDING COMMON SHARES ON A FULLY-DILUTED BASIS WERE TAKEN UP BY THE OFFEROR ON OCTOBER 17, 2011.

This notice of extension (the "**Notice of Extension**") should be read in conjunction with the Notice of Variation, the Original Offer, the accompanying circular dated September 6, 2011 (the "**Circular**" and, together with the Original Offer, the "**Original Offer and Circular**"), and the associated letter of transmittal (the "**Letter of Transmittal**") and notice of guaranteed delivery (the "**Notice of Guaranteed Delivery**") (collectively, the "**Original Offer Documents**"). Except as otherwise set forth herein, the terms and conditions previously set forth in the Original Offer Documents continue to be applicable in all respects. Unless the context otherwise requires, references in this document to the "**Offer**" mean the Original Offer and Circular, as amended or amended and varied by the Notice of Variation and this Notice of Extension. Unless the context requires otherwise, capitalized terms used herein but not defined herein have the respective meanings set out in the Original Offer and Circular, as amended by the Notice of Variation.

If you have validly deposited and not withdrawn Common Shares under the Offer, you do not need to take any further action to accept the Offer and will automatically be entitled to receive under the Offer the consideration of \$0.85 per Common Share.

Shareholders who wish to accept the Offer must properly complete and execute the Letter of Transmittal (printed on yellow paper) or a manually signed facsimile and deposit it, together with the certificates representing their Common Shares, in accordance with the instructions in the Letter of Transmittal or Shareholders may follow the procedure for guaranteed delivery described under Section 3 of the Offer, "Manner of Acceptance — Procedure for Guaranteed Delivery". Alternatively, Shareholders whose Common Shares are registered in the name of CDS or DTC may accept the Offer by following the procedures for book-entry transfer described under Section 3 of the Offer, "Manner of Acceptance — Book-Entry Transfers". The Letter of Transmittal and Notice of Guaranteed Delivery that accompanied the Offer and Circular, each as amended by this Notice of Extension, are deemed to be amended to reflect the terms and conditions of this Notice of Extension.

Shareholders whose Common Shares are registered in the name of an investment dealer, stockbroker, bank, trust company or other nominee should contact that nominee for assistance if they wish to accept the Offer.

Questions and requests for assistance may be directed to Computershare Investor Services Inc. (the "**Depositary**") or Afexa's information agent, Georgeson Shareholder Communication Inc. ("**Afexa's Information Agent**"). Contact details for such persons may be found on the last page of this document. Additional copies of the Original Offer Documents, the Notice of Variation and this Notice of Extension may be obtained without charge upon request from the Depositary or Afexa's Information Agent at their respective address shown on the last page of this document. Additionally, copies of this document and related materials may be found at www.sedar.com.

This document does not constitute an offer or a solicitation to any person in any jurisdiction in which such offer or solicitation is unlawful. The Offer is not being made to, nor will deposits be accepted from or on behalf of, Shareholders in any jurisdiction in which the making or acceptance of the Offer would not be in compliance with the Laws of such jurisdiction. However, the Offeror or its agents may, in the Offeror's sole discretion, take such action as the Offeror may deem necessary to extend the Offer to Shareholders in such jurisdictions.

The Offeror has not authorized anyone to provide any information or make any representation about the Offer or the Offeror, Valeant or their affiliates that is different from, or in addition to, the information and representations contained in the Offer or in any materials regarding the Offer or the Offeror, Valeant or their affiliates accompanying this document. Shareholders should not rely on any information or any representations regarding the Offer or the Offeror, Valeant or their affiliates not contained in the Offer or in the documents accompanying the Offer.

Unless otherwise specifically indicated, the information contained in this document is given as of the date of this document, and the Offeror undertakes no duty to update any such information, except as required by applicable Law.

NOTICE TO SHAREHOLDERS IN THE UNITED STATES

The Offer is being made for the securities of a Canadian issuer and the Offer is subject to Canadian disclosure requirements. Shareholders should be aware that such disclosure requirements are different from those of the United States.

The enforcement by Shareholders of civil liabilities under the United States federal securities laws may be affected adversely by the fact that the Depositary and Afexa's Information Agent named in the Offer or Circular may not be residents of the United States, and that all or a substantial portion of the assets of the Offeror and of said persons may be located outside the United States. The enforcement by Shareholders of civil liabilities under the United States federal securities laws may also be affected adversely by the fact that Afexa is incorporated under the *Business Corporations Act* (Alberta) and that some or all of its officers and directors may be residents of Canada or other jurisdictions outside the United States.

CURRENCY AND EXCHANGE RATES

All dollar references in the Notice of Extension, the Notice of Variation and the Original Offer and Circular are in Canadian dollars, unless otherwise indicated. On October 17, 2011, the rate of exchange for the Canadian dollar, expressed in U.S. dollars, based on the noon rate as provided by the Bank of Canada was \$1.00 = US\$ 0.9850.

FORWARD-LOOKING STATEMENTS

Certain statements in this Notice of Extension, the Notice of Variation and in the Original Offer and Circular (as well as in oral statements or other written statements made or provided or to be made or provided by the Offeror or Valeant), are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events, and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as "may", "should", "will", "could", "intend", "estimate", "plan", "anticipate", "expect", "believe" or "continue", or the negative thereof or similar variations. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Such forward-looking statements should therefore be construed in light of such factors, and the Offeror and Valeant are under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

NOTICE OF EXTENSION

This Notice of Extension should be carefully read in conjunction with the Notice of Variation and the Original Offer and Circular and the Letter of Transmittal and Notice of Guaranteed Delivery that accompanied the Original Offer and Circular as amended by the Notice of Variation and this Notice of Extension.

October 17, 2011

TO THE HOLDERS OF COMMON SHARES OF AFEXA LIFE SCIENCES INC.:

By written notice to the Depository given on October 17, 2011 and as set forth in this Notice of Extension, the Offeror extends the period for acceptance of its Original Offer, as amended by the Notice of Variation, to purchase all of the issued and outstanding Common Shares, including Common Shares issued after the date of the Original Offer but prior to the Expiry Time upon the conversion, exchange or exercise of any other securities that are convertible into or exchangeable or exercisable for Common Shares.

Except as otherwise set forth in this Notice of Extension, the information, terms and conditions in the Original Offer and Circular and the Letter of Transmittal and Notice of Guaranteed Delivery that accompanied the Original Offer and Circular, each as amended by the Notice of Variation, continue to be applicable in all respects.

Unless otherwise defined herein or amended hereby, defined terms used in this Notice of Extension have the same meaning as in the Original Offer and Circular, as amended by the Notice of Variation. The term "**Offer**" means the Offer, as expressly amended or supplemented by the Notice of Variation and this Notice of Extension.

1. EXTENSION OF THE OFFER

The Offeror has extended the expiry time of the Offer from 5:00 p.m. (Edmonton time) on October 17, 2011 to 5:00 p.m. (Edmonton time) on October 27, 2011. Accordingly, the definition of "**Expiry Date**" in the Original Offer and Circular, as amended by the Notice of Variation, is deleted in its entirety and replaced with the following definition:

"**Expiry Date**" means October 27, 2011 or such later date or dates as may be fixed by the Offeror from time to time pursuant to Section 5 of the Offer, "Extension, Variation or Change in the Offer".

Section 2 of the Original Offer and Circular "Time for Acceptance", as amended by the Notice of Variation, is deleted in its entirety and replaced with the following:

"The Offer is open for acceptance until the Expiry Time on the Expiry Date, being 5:00 p.m. (Edmonton time) on October 27, 2011, or until such later time and date or times and dates to which the Offer may be extended at the Offeror's sole discretion, not to exceed the Outside Date, pursuant to Section 5 of the Offer, "Extension, Variation or Change in the Offer", unless the Offer is withdrawn by the Offeror."

In addition, all references to "5:00 p.m. (Edmonton Time) on October 17, 2011" in the Original Offer and Circular and the Letter of Transmittal and the Notice of Guaranteed Delivery that accompanied the Original Offer and Circular, each as amended by the Notice of Variation, are amended to reference "5:00 p.m. (Edmonton time) on October 27, 2011".

2. RECENT DEVELOPMENTS

Paladin Offer

On October 3, 2011, Paladin announced that it would not take up any Common Shares under its revised offer to acquire the Common Shares of Afexa due to a non-fulfillment of a condition to its revised offer.

Take-up and payment of Common Shares

Valeant announced on October 17, 2011 that a total of 80,929,921 Common Shares were validly deposited at the Expiry Time of the Offer. As all of the conditions of the Offer have been satisfied, the Offeror has taken up all of the deposited Common Shares.

Accordingly, after giving effect to the take-up of the deposited Common Shares, the Offeror holds approximately 73.8% of the outstanding Common Shares on a Fully-Diluted Basis and will appoint six of the eight members of the board of directors of Afexa in accordance with the terms of the Support Agreement. The Offeror is in a position to privatize Afexa by completing a Subsequent Acquisition Transaction as contemplated in the Original Offer and Circular.

If further to the extension of the Offer pursuant to this Notice of Extension, the Offeror is successful in acquiring at least 90% of the outstanding Common Shares under the Offer, it intends to acquire the remaining Common Shares by way of Compulsory Acquisition under the ABCA. If the Offeror does not acquire at least 90% of the outstanding Common Shares, the Offeror intends to privatize Afexa by completing a Subsequent Acquisition Transaction as contemplated in the Original Offer and Circular. Following either a Compulsory Acquisition, or a Subsequent Acquisition Transaction, the Common Shares will be delisted from the Toronto Stock Exchange and application will be made to the relevant securities regulatory authorities for Afexa to cease to be a reporting issuer. The Offeror does not intend to pay more than \$0.85 per share and all Afexa shareholders who have not yet tendered their Common Shares to the Offer are encouraged to do so as soon as possible in order to receive prompt payment.

3. MANNER OF ACCEPTANCE

Common Shares may be deposited under the Offer in accordance with the provisions under Section 3 of the Offer, "Manner of Acceptance".

If you have validly deposited your Common Shares and not withdrawn such Common Shares under the Offer, you do not need to take any further action to accept the Offer. Any Common Shares that you have tendered will automatically be entitled to receive under the Offer the consideration of \$0.85 per Common Share.

4. TAKE-UP OF AND PAYMENT FOR DEPOSITED COMMON SHARES

The Offeror will take up and pay for Common Shares duly and validly deposited pursuant to the Offer in accordance with the terms of the Offer and not withdrawn pursuant to Section 8 of the Offer, "Right to Withdraw Deposited Common Shares".

All conditions referred to in Section 4 of the Offer, "Conditions of the Offer" have been fulfilled or waived as of 5:00 p.m. (Edmonton time) on October 17, 2011. Accordingly, on October 17, 2011, the Offeror took up Common Shares validly deposited under the Offer and not withdrawn. Any Common Shares duly and validly deposited and not withdrawn after October 17, 2011 but prior to 5:00 p.m. (Edmonton time) on October 27, 2011 will be taken up and paid for not later than 10 days after the deposit of such Common Shares.

Shareholders are referred to Section 6 of the Offer, "Take up and Payment for Deposited Common Shares" for details as to take-up of and payment for Common Shares under the Offer.

5. RIGHT TO WITHDRAW DEPOSITED COMMON SHARES

Except as otherwise provided in Section 8 of the Offer, "Right to Withdraw Deposited Common Shares", all deposits of Common Shares pursuant to the Offer are irrevocable. Unless otherwise required or permitted by applicable Laws, any Common Shares deposited in acceptance of the Offer may be withdrawn at the place of deposit by or on behalf of the depositing Shareholders:

- a) at any time when the Deposited Common Shares have not been taken up by the Offeror under the Offer;

- b) if the Deposited Common Shares have not been paid for by the Offeror within three (3) business days after having been taken up; or
- c) at any time before the expiration of ten (10) days from the date upon which either:
 - i. a notice of change relating to a change which has occurred in the information contained in the Offer or the Circular, as amended from time to time, that would reasonably be expected to affect the decision of a Shareholder to accept or reject the Offer (other than a change that is not within the control of the Offeror or an affiliate of the Offeror), in the event that such change occurs before the Expiry Time or after the Expiry Time but before the expiry of all rights of withdrawal in respect of the Offer; or
 - ii. a notice of variation concerning a variation in the terms of the Offer (other than (A) a variation consisting solely of an increase in the consideration offered where the Expiry Time is not extended for more than 10 days and (B) a variation in the terms of the Offer consisting solely of the waiver of one or more of the conditions of the Offer),

is mailed, delivered or otherwise properly communicated (subject to abridgement of that period pursuant to such order or orders as may be granted by applicable courts or securities regulatory authorities) but only if such Deposited Common Shares have not been taken up by the Offeror at the date of the notice.

Shareholders should refer to Section 8 of the Offer, "Right to Withdraw Deposited Common Shares" for details and a description of the procedures for exercising the right to withdraw Common Shares under the Offer.

6. CONSEQUENTIAL AMENDMENTS AND VARIATIONS TO ORIGINAL OFFER DOCUMENTS

The Original Offer and Circular, the Letter of Transmittal and the Notice of Guaranteed Delivery that accompanied the Original Offer and Circular, each as amended by the Notice of Variation, shall be read together with this Notice of Extension, and amended to the extent necessary, in order to give effect to the amendments and supplements set forth in this Notice of Extension. Except as otherwise set forth in or amended by this Notice of Extension, the terms and conditions of the Original Offer and the information in the Original Offer and Circular, the Letter of Transmittal and the Notice of Guaranteed Delivery that accompanied the Original Offer and Circular, each as amended by the Notice of Variation, continue to be applicable in all respects.

7. STATUTORY RIGHTS

Securities legislation in the provinces and territories of Canada provides Shareholders with, in addition to any other rights they may have at law, one or more rights of rescission, price revision or to damages, if there is a misrepresentation in a circular or notice that is required to be delivered to those Shareholders. However, such rights must be exercised within prescribed time limits. Shareholders should refer to the applicable provisions of the securities legislation of their province or territory for particulars of those rights or consult a lawyer.

APPROVAL AND CERTIFICATE OF 1625907 ALBERTA LTD.

Dated: October 17, 2011

The contents of the Notice of Extension together with the Original Offer and Circular and the Notice of Variation, have been approved and the sending, communication or delivery thereof to the Shareholders has been authorized by the board of directors of 1625907 Alberta Ltd.

The Notice of Extension together with the Original Offer and Circular and the Notice of Variation, contains no untrue statement of a material fact and does not omit to state a material fact that is required to be stated or that is necessary to make a statement not misleading in the light of the circumstances in which it is made.

1625907 Alberta Ltd.

(Signed) J. Michael Pearson
Chief Executive Officer

(Signed) Livio DiFrancesco
Vice President, Finance

On behalf of the Board of Directors

(Signed) Rajiv De Silva
Director

(Signed) Robert Chai-Onn
Director

APPROVAL AND CERTIFICATE OF VALEANT PHARMACEUTICALS INTERNATIONAL, INC.

Dated: October 17, 2011

The contents of the Notice of Extension together with the Original Offer and Circular and the Notice of Variation, have been approved and the sending, communication or delivery thereof to the Shareholders has been authorized by the board of directors of Valeant Pharmaceuticals International, Inc.

The Notice of Extension together with the Original Offer and Circular and the Notice of Variation, contains no untrue statement of a material fact and does not omit to state a material fact that is required to be stated or that is necessary to make a statement not misleading in the light of the circumstances in which it is made.

VALEANT PHARMACEUTICALS INTERNATIONAL, INC.

(Signed) J. Michael Pearson
Chairman and Chief Executive Officer

(Signed) Philip W. Loberg
Executive Vice President and Interim
Chief Financial Officer

On behalf of the Board of Directors

(Signed) G. Mason Morfit
Director

(Signed) Lloyd Segal
Director

Any questions and requests for assistance may be directed to Afexa's Information Agent:



100 University Avenue
11th Floor, South Tower
Toronto, Ontario M5J 2Y1

North American Toll Free Number: 1-866-676-3005
Email: askus@georgeson.com

The Depositary for the Offer is:

Inquiries:

COMPUTERSHARE INVESTOR SERVICES INC.

Toll Free (North America): 1-800-564-6253
E-Mail: corporateactions@computershare.com
Website: www.computershare.com

By Mail:

Computershare Investor Services Inc.
P.O. Box 7021, 31 Adelaide St E
Toronto, ON M5C 3H2

Attention: Corporate Actions

By Hand, by Courier or by Registered Mail:

Computershare Investor Services Inc.
9th Floor, 100 University Avenue
Toronto, Ontario M5J 2Y1

Attention: Corporate Actions